Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

Clover Biopharmaceuticals, Ltd. a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. Announced that enrollment of the first participants has...

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Shanghai Ark Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for...

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the...

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

with BOOST Pharma’s clinical and future commercial goals. About BOOST Pharma ApS BOOST Pharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a...

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and...

Matisse Pharmaceuticals receives INN for M6229, recognizing it as a first-in-class drug, isupartob sodium

Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, announced that Matisse’s lead compound M6229, has received the International Non-proprietary Name (INN) isupartob sodium from the...

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

Servier, an independent international pharmaceutical group governed by a foundation, announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony...

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

is approved for the treatment of all indications approved for Eylea. About Celltrion Inc. Celltrion is a leading biopharmaceutical company that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics...

Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

canal Atypical fractures of the femur About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development...

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

The Menarini Group a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer...

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial...

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

pre-qualified iPSC-derived cells and Emulate’s proprietary BMECs form the foundation of the Brain-Chip R1, providing pharmaceutical researchers with a highly human-relevant model to advance CNS drug discovery. “Our iCell® human iPSC-derived...

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, announced that Health Canada has approved KYZATREX® (testosterone undecanoate) CIII capsules. KYZATREX is a...

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

(PES) membrane that achieves both high permeability and robust virus retention, advancing efficiency and safety in biopharmaceutical manufacturing. FG1 builds on the legacy of the Planova™ series — the world’s first virus removal filter, introduced...

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology,...

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

(TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead remains devoted to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

pharmacologic classes, including chlorthalidone. About PRM Pharma, LLC PRM Pharma, LLC is a privately held specialty pharmaceutical company focused on developing low-dose therapies that align with clinical practice guidelines and advance patient...

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...